Sight Sciences (NASDAQ:SGHT) Stock: Insider Brenton Taylor Sells 20,685 Shares

Sight Sciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Insider Brenton Taylor sold 20,685 Sight Sciences shares at an average $10.64, worth about $220,088. He retained 241,305 shares after the sale, a 7.9% reduction in his position.
  • Sight Sciences reported quarterly EPS of -$0.12, in line with estimates, while revenue of $24.92 million topped the $23.55 million analyst forecast.
  • Analysts’ consensus rating was Moderate Buy, with an average price target of $10.31; shares traded at $10.77 in the article.
  • MarketBeat previews top five stocks to own in December.

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) EVP Brenton Taylor sold 20,685 shares of the firm's stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $10.64, for a total transaction of $220,088.40. Following the sale, the executive vice president owned 241,305 shares in the company, valued at approximately $2,567,485.20. This trade represents a 7.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Brenton Taylor also recently made the following trade(s):

  • On Friday, October 2nd, Brenton Taylor sold 2,988 shares of Sight Sciences stock. The stock was sold at an average price of $8.85, for a total value of $26,443.80.

Sight Sciences Stock Up 2.7%

SGHT traded up $0.28 on Wednesday, reaching $10.77. The company's stock had a trading volume of 335,567 shares, compared to its average volume of 285,342. The stock has a market cap of $598.60 million, a price-to-earnings ratio of -20.71 and a beta of 2.44. Sight Sciences, Inc. has a 1 year low of $3.38 and a 1 year high of $11.60. The business's 50 day moving average is $9.06 and its 200 day moving average is $6.25. The company has a debt-to-equity ratio of 0.71, a current ratio of 5.04 and a quick ratio of 4.72.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). The business had revenue of $24.92 million during the quarter, compared to analyst estimates of $23.55 million. Sight Sciences had a negative net margin of 32.13% and a negative return on equity of 43.91%. As a group, research analysts forecast that Sight Sciences, Inc. will post -0.48 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on the stock. HC Wainwright began coverage on shares of Sight Sciences in a research note on Thursday, October 15th. They set a "buy" rating and a $14.00 price objective for the company. UBS Group boosted their price target on shares of Sight Sciences from $8.00 to $13.50 and gave the company a "buy" rating in a report on Thursday, November 12th. Piper Sandler restated an "overweight" rating and set a $12.00 price target (up from $9.00) on shares of Sight Sciences in a report on Thursday, November 5th. Citigroup boosted their target price on shares of Sight Sciences from $8.00 to $10.00 and gave the stock a "neutral" rating in a research report on Monday, October 5th. Finally, Wall Street Zen cut shares of Sight Sciences from a "buy" rating to a "hold" rating in a report on Saturday. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $10.31.

Check Out Our Latest Research Report on Sight Sciences

Institutional Trading of Sight Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Conquis Financial LLC acquired a new position in Sight Sciences during the second quarter valued at approximately $27,000. The Manufacturers Life Insurance Company acquired a new position in shares of Sight Sciences in the second quarter valued at approximately $60,000. Ieq Capital LLC bought a new stake in shares of Sight Sciences in the second quarter valued at about $135,000. Hsbc Holdings PLC bought a new position in shares of Sight Sciences during the first quarter worth approximately $147,000. Finally, Algert Global LLC lifted its position in shares of Sight Sciences by 25.3% during the 2nd quarter. Algert Global LLC now owns 28,266 shares of the company's stock valued at $153,000 after acquiring an additional 5,706 shares during the period. 55.51% of the stock is owned by institutional investors.

Sight Sciences Company Profile

(Get Free Report)

Sight Sciences is a medical technology company that develops and commercializes devices for ophthalmic care, with a focus on glaucoma and dry eye disease. Its products are designed to support minimally invasive procedures and address underlying causes of these conditions. The company's portfolio includes the OMNI Surgical System, used in procedures to reduce eye pressure in patients with glaucoma, and TearCare, a device-based treatment for evaporative dry eye associated with meibomian gland dysfunction.

Read More

Insider Buying and Selling by Quarter for Sight Sciences (NASDAQ:SGHT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Sight Sciences Right Now?

Before you consider Sight Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sight Sciences wasn't on the list.

While Sight Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines